---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-126358"
form_type: "8-K"
ticker: "BJDX"
cik: "0001704287"
company_name: "Bluejay Diagnostics, Inc."
filed_at: "2025-12-30T23:59:59+00:00"
generated_at: "2026-05-16T12:00:17.362060+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Bluejay Diagnostics completes commercial-scale IL-6 antibody production for Symphony cartridges

## Summary
- Completed commercial-scale production of polyclonal and monoclonal anti-IL-6 antibodies meeting internal performance criteria.
- Antibodies intended for Symphony cartridge manufacturing for clinical and potential future commercial applications.
- Sufficient material to support production of over 9 million Symphony cartridges; additional capacity established.
- Symphony System remains under development, subject to further validation and FDA clearance before marketing.
- Monoclonal antibodies designated as detection antibodies showed acceptable binding, specificity, and signal performance.

## SEC filing metadata
- accession: 0001213900-25-126358
- form_type: 8-K
- ticker: BJDX
- cik: 0001704287
- company_name: Bluejay Diagnostics, Inc.
- filed_at: 2025-12-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704287/000121390025126358/0001213900-25-126358-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704287/000121390025126358/ea0271231-8k_bluejay.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-126358
- JSON: https://secwatch.observer/filing/0001213900-25-126358.json
- Plain text: https://secwatch.observer/filing/0001213900-25-126358.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.